Tirzepatide
Brand name: Mounjaro
Rank #17 of 500 drugs by total cost
$877.9M
Total Cost
680,457
Total Claims
$877.9M
Total Cost
19,800
Prescribers
$1,290
Cost per Claim
73,129
Beneficiaries
800,635
30-Day Fills
$44K
Avg Cost/Provider
34
Avg Claims/Provider
About Tirzepatide
Tirzepatide (sold as Mounjaro) was prescribed 680,457 times by 19,800 Medicare Part D providers in 2023, costing the program $877.9M. At $1,290 per claim, this is a high-cost medication.
Related Drugs by Cost
| # | Drug | Total Cost | Claims |
|---|---|---|---|
| 14 | Etanercept (Enbrel Sureclick) | $1.12B | 145,737 |
| 15 | Enzalutamide (Xtandi) | $985.0M | 72,710 |
| 16 | Mirabegron (Myrbetriq) | $927.5M | 1,407,073 |
| 17 | Tirzepatide (Mounjaro) | $877.9M | 680,457 |
| 18 | Ibrutinib (Imbruvica) | $875.8M | 56,368 |
| 19 | Ustekinumab (Stelara) | $852.3M | 31,974 |
| 20 | Paliperidone Palmitate (Invega Sustenna) | $832.3M | 252,388 |
Data from CMS Medicare Part D Prescriber-Drug Public Use File, 2023. Methodology